L3VLUP
ProSign in

NVCR · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVCRLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVCR
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterNVCRLLY
Q3 202010 holders, $3.0bn33 holders, $14.1bn
Q4 20208 holders, $4.6bn29 holders, $17.3bn
Q1 20217 holders, $3.7bn24 holders, $23.0bn
Q2 20218 holders, $7.3bn24 holders, $27.8bn
Q3 20218 holders, $3.6bn31 holders, $29.9bn
Q4 20216 holders, $2.3bn31 holders, $34.7bn
Q1 20225 holders, $2.7bn24 holders, $35.3bn
Q2 20229 holders, $2.4bn33 holders, $42.7bn
Q3 20226 holders, $3.0bn31 holders, $43.4bn
Q4 20226 holders, $2.9bn31 holders, $46.6bn
Q1 20237 holders, $2.5bn33 holders, $44.3bn
Q2 20237 holders, $1.6bn37 holders, $59.6bn
Q3 20238 holders, $329m44 holders, $67.6bn
Q4 202310 holders, $205m45 holders, $73.6bn
Q1 20249 holders, $145m41 holders, $95.3bn
Q2 20247 holders, $145m43 holders, $110bn
Q3 20247 holders, $142m45 holders, $107bn
Q4 20248 holders, $758m46 holders, $93.9bn
Q1 20256 holders, $198m42 holders, $98.4bn
Q2 20254 holders, $187m43 holders, $93.2bn
Q3 20253 holders, $43m39 holders, $86.7bn
Q4 20253 holders, $18m41 holders, $123bn
Q1 20262 holders, $12m39 holders, $106bn
Q2 20262 holders, $15m44 holders, $132bn
NVCR

Novocure Ltd

Holders
9
Reported value
$145m
Buyers
4
Sellers
5

Breadth -1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVCR (5)

Baillie Gifford & Co, ExodusPoint Capital Management LP, PDT Partners LLC, Quantbot Technologies LP, Voloridge Investment Management LLC

Only LLY (37)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, and 12 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →